Clinical Trial Search

Primary: Hearing Performance: Threshold Audiometry, Pure Tone Average of 4 Frequencies, PTA4, Unaided Versus OSIA System at 3 Months — -25.8 dB (Decibel) — p=<0.0001

Primary: Usage of NOAC Based on Baseline Characteristics: Age at the Time of the First NOAC Initiation — 72.8; 72.5; 72.6; 74.0 Years

Primary: Biochemical Markers of Bone Turnover — -6.25; -3.36; -0.14; 0.5 nmol/mmol

Primary: Intraocular Pressure — -1.85 mmHg

Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001

Primary: Mean Percentage of Perforin+ CD4+ and CD8+ T Cells After Stimulation With M-001 Component Peptides — 1.180; 0.781; 1.090; 0.779 percentage of cells — p=0.53

Primary: Delay Discounting — -4.84 score on a scale (natural log)

Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12

Primary: Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo — 32.5; 39.0 percentage of participants — p=0.8000

Primary: Abbreviated Profile of Hearing Aid Benefit (APHAB) — 6.3; 7.0; 5.6; 3.5 units on a scale

Primary: Observed Photoallergy (Photosensitization): Number of Skin Sites by Maximum Total Irritation Score — 10; 3; 1; 0 Number of affected skin sites

Primary: Percentage of Participants Whose Change in Pain Rating on the Visual Analog Scale (VAS) Met the Individual Subject Success Criteria — 21; 8 Participants — p=<0.005

Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM

Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants

Primary: Visual Analog Numeric Pain Score — 6.1; 5.7; 5.2; 5.1 score on a scale